For the first-time a human study shows the reversal in the biology of aging, with hyperbaric oxygen therapy (HBOT)
In a scientifically verified approach, signaling an important breakthrough in the study of aging, Tel Aviv University and The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center announced today that, for the first time in humans, two key biological hallmarks of aging, telomere length shortening, and accumulation of senescent cells, can be reversed. The prospective clinical trial, published in peer-reviewed Journal Aging, utilizes Hyperbaric Oxygen Therapy protocols to demonstrate cellular level improvement in healthy aging adults.
Hyperbaric Oxygen Therapy targets aging as a reversible disease
The prospective clinical trial is part of a comprehensive aging research program taking place in Israel. It was conducted by Prof. Shai Efrati, MD, from the Faculty of Medicine and Sagol School of Neuroscience at Tel Aviv University, and Amir Hadanny, MD, Chief Medical Research Officer of The Sagol Center for Hyperbaric Medicine and Research and co-author of the study. Using a specific protocol of hyperbaric oxygen therapy (HBOT), telomere length was significantly increased and senescent cells were reduced in a population of healthy aging subjects. The study was published in the peer-reviewed journal Aging. Titled: Hyperbaric Oxygen Therapy Increases Telomere Length and Decreases Immunosenescence in Isolated Blood Cells: A Prospective Trial.
So Michael Jackson was right all the time?